Novanta Completes Riverpoint Medical Acquisition, Expanding Minimally Invasive Surgery Portfolio

The Quick Take

• Novanta Inc. (Nasdaq: NOVT) has completed its acquisition of Riverpoint Medical from Arlington Capital Partners, expanding its medical device precision technology portfolio.
• Riverpoint Medical specializes in advanced surgical braids, sutures, and minimally invasive surgery tools — complementing Novanta's existing medical laser and motion systems.
• The acquisition extends Novanta's positioning as a trusted technology partner to medical and advanced equipment manufacturers globally.
• Novanta's M&A strategy focuses on technology-adjacent medical device acquisitions that scale its precision engineering capabilities.

Novanta Inc. has formally completed the acquisition of Riverpoint Medical, a specialist manufacturer of advanced surgical braids, sutures, and minimally invasive surgery enabling technologies, from Arlington Capital Partners. The transaction strengthens Novanta's position as a precision technology partner to surgical equipment OEMs — a strategy that has consistently driven inorganic revenue growth for the Boston-headquartered company. Novanta's customer base spans leading medical device companies that rely on precision laser, motion, and sensing subsystems, and Riverpoint's minimally invasive surgery portfolio extends that value proposition into the procedural consumables layer.

For Canadian investors following Novanta through its Financial Post coverage, the acquisition is a read on the continued strategic consolidation in the medical technology precision components space. The MedTech M&A cycle has been active in 2025-2026 as larger OEMs seek to vertically integrate precision subsystems rather than source them from independent vendors. Novanta's Arlington Capital Partners target was previously a private equity-held asset, which typically implies a disciplined valuation process and a management team with integration experience. The deal also diversifies Novanta's revenue across surgical specialties beyond its core laser and motion systems businesses.

The key metric to monitor following the close is Novanta's post-acquisition revenue contribution disclosure in its next quarterly earnings. The critical question is whether Riverpoint's surgical consumables business carries margin profiles comparable to Novanta's existing precision technology divisions or represents a dilutive mix shift. Watch Novanta's next earnings call for integration timeline guidance, cross-selling opportunity quantification, and any synergy target update. The macro variable is US hospital capital spending — a primary determinant of demand for surgical upgrade programs that create Novanta's end-market pull.

Synthesized from 1 source.